CorMedix Inc. (NASDAQ:CRMD) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and General Counsel Elizabeth Hulbert - EVP, Clinical and Medical Affairs Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler - JMP Securities Joon Lee - Truist Secur ...

On February 28, 2022, we resubmitted the NDA for DefenCath to address the CRL issued by the FDA. In parallel, our thirdparty manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the PAAL issued by the FDA concurrently with the CRL. On March 28, 2022, we announced that the resubmission of the NDA for DefenCath had been accepted for filing by the FDA. The FDA considered the resubmission as a complete, Class 2 response with a six-month review cycle. The CMO notified ...

CorMedix Inc. (NASDAQ:CRMD) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and General Counsel Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the CorMedix First Quarter 2023 Earnings Conference Call. All participants will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 For the transition period from ________ to ________ | --- | --- | |--------------------------------------------------------------|-----------------------| | Delaware | 20-5894890 | | (State or Other Jurisdiction of Incorporation or | (I.R.S. Employer | | Organization) | Identificati ...

CorMedix Inc. (NASDAQ:CRMD) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Phoebe Mounts – Executive Vice President and General Counsel Erin Mistry – Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler – JMP Securities Joon Lee – Truist Securities Serge Belanger – Needham & Co. Opera ...

CorMedix Inc. (NASDAQ:CRMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Phoebe Mounts - Executive Vice President, General Counsel Erin Mistry - Senior Vice President, Commercial Daniel Ferry - LifeSci Advisors Conference Call Participants Assam - Truist Securities Jason Butler - JMP Securities Serge Belanger - Needham & Co. Operator Good morning and welcome to the CorMe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 20-5894890 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value CRMD Nasdaq Global Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging Growth Company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION ...

CorMedix Inc. (NASDAQ:CRMD) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors, LLC Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade Joseph Todisco - Chief Executive Officer Matt David - Executive Vice President & Chief Financial Officer Phoebe Mounts - Executive Vice President & General Counsel Conference Call Participants Rohit Bhasin - Needham & Co. Operator Greetings and welcome to the CorMedix Inc. S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | --- | |------------------ ...

CorMedix Inc. (NASDAQ:CRMD) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade Conference Call Participants Jason Butler - JMP Securities Rohit Bhasin - Needham & Company Operator Hello and welcome to the CorMedix Inc. First Quarter 2022 Earnings Call and ...